Bracco Endorses ASNC Position Statement for Cardiac PET Advancement in Coronary Artery Disease Management

Bracco's Commitment to Advancing Cardiac Imaging

Bracco, a recognized pioneer in diagnostic imaging, has long been on the forefront of cardiac positron emission tomography (PET). The company recently affirmed its pivotal role with the American Society of Nuclear Cardiology (ASNC) Position Statement recommending cardiac PET with myocardial blood flow (MBF) quantification as the standard for evaluating coronary artery disease (CAD). Published on April 13, 2026, this statement reflects the accumulation of evidence supporting the enhanced diagnostic capabilities of cardiac PET over alternative methods, particularly single photon emission computed tomography (SPECT).

The ASNC guidance marks a transformative moment in cardiovascular imaging. As clinical evidence shows, cardiac PET provides superior accuracy in detecting heart disease, interpreting complex cases, especially in patients with obesity or smaller vessel diseases. No clinical scenarios exclude the use of PET MPI, given its unique ability to deliver critical insights regarding diagnostic accuracy and patient risk stratification. According to Dr. Nils Johnson, an interventional cardiologist, this advancement is a game-changer for diagnosing coronary artery disease in 2026.

Bracco has been advocating a comprehensive approach to cardiac imaging since 1989. Their portfolio integrates leading technologies like Cardiogen-82® (Rubidium Rb 82 generator) for myocardial perfusion imaging with HeartSee™, a state-of-the-art platform that generates clear Coronary Flow Capacity (CFC) maps. These innovations facilitate the assessment of coronary defects and severity of heart disease alongside classical diagnostic methodologies.

Fulvio Renoldi Bracco, CEO of Bracco Imaging S.p.A, stated, “The ASNC's strong recommendation validates our comprehensive approach integrating advanced PET imaging with quantitative blood flow assessment, enhancing diagnostic outcomes globally.” This statement not only underscores Bracco's commitment but also sets a new benchmark for imaging practices and patient care.

The Key Takeaways

1. Improved Diagnostic Accuracy: Cardiac PET surpasses traditional imaging methods in detecting CAD, which is crucial in managing heart-related conditions effectively.
2. Applicable to All Patients: The statement emphasizes that there are no limitations on using PET MRI across various patient demographics.
3. Leading Innovations: Bracco’s integrated technologies combine clinical education, advances in reimbursement structures, and widespread access to imaging solutions.

As a pioneer in the world of diagnostic imaging, Bracco has dedicated itself to enhancing patients' lives through innovative solutions in prevention and precision medicine. With a presence in over 100 countries with 3,800 employees, they continue to shape the future of radiology.

For those interested in accessing Bracco's extensive resources and product portfolio, further information can be found on their official website. This commitment not only inspires confidence in healthcare providers but also ensures patients receive the best possible care—setting a new standard for cardiac imaging in the years to come.

Important Safety Information

Utilizing the CARDIOGEN-82® (Rubidium Rb 82 Generator) requires caution. There are risks related to incorrect eluent use which can lead to high radiation exposure. Following the proper testing protocols is essential to ensure safety during cardiac imaging procedures.

In summary, Bracco’s strong endorsement of the ASNC's guidance reinforces their strategic role in advancing cardiac PET imaging. As the healthcare community embraces these changes, improved patient outcomes and diagnostic accuracy in coronary artery disease evaluation are now more achievable than ever.